Reuters
Published Apr 05, 2024 05:49PM ET
Updated Apr 05, 2024 06:00PM ET
By Blake Brittain
(Reuters) - Apple (NASDAQ:AAPL) urged a U.S. appeals court on Friday to overturn a U.S. trade tribunal's decision to ban imports of some Apple Watches in a patent dispute with medical-monitoring technology company Masimo (NASDAQ:MASI).
Apple told the U.S. Court of Appeals for the Federal Circuit that the U.S. International Trade Commission's decision was based on a "series of substantively defective patent rulings," and that Masimo failed to show it had invested in making competing U.S. products that would justify the order.
Representatives for Apple and Masimo did not immediately respond to requests for comment on the filing.
Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology after discussing a potential collaboration. Apple first introduced pulse oximetry to its Series 6 Apple Watches in 2020.
Masimo convinced the ITC on Dec. 26 to block imports of Apple's latest-edition Series 9 and Ultra 2 smartwatches after finding that their technology for reading blood-oxygen levels infringed Masimo's patents.
Apple temporarily resumed sales of the watches the next day after persuading the Federal Circuit to pause the ban. The appeals court reinstated the ban in January, leading Apple to remove pulse oximetry capabilities from watches sold during the appeal, which Apple has said could last at least a year.
U.S. Customs and Border Protection separately determined in January that redesigned versions of the watches did not violate Masimo's rights and would not be not subject to the ban. Masimo said in a court filing that the watches "definitively do not contain pulse oximetry functionality."
Apple told the Federal Circuit on Friday that the ban could not stand because a Masimo wearable covered by the patents was "purely hypothetical" when it filed its ITC complaint in 2021.
The tech giant also argued that Masimo's patents were invalid and that its watches did not infringe them.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.